Clinical Trials Arena on MSN3d
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200
Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...
Ophthalmology Times10d
Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular edema treatment
Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...
Medscape21d
Efficacy and Safety of Widely Used Treatments for Macular Oedema Secondary to Retinal Vein Occlusion
It is important to consider the relative efficacy of the available therapies for RVO with published data. This systematic review was therefore performed to assess the efficacy and safety of ...
Hosted on MSN1mon
Regeneron’s macular oedema therapy shows promise in Phase III trial
Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal vein ...
The American Journal of Managed Care16d
Racial, Ethnic Minorities Underrepresented in Clinical Trials in Macular Edema
Racial and ethnic minorities are underrepresented in DRCRnet DME trials, despite experiencing more severe symptoms than other ...
pharmaphorum12d
Europe has its first Lucentis biosimilar, Samsung Bioepis' Byooviz
and diabetic macular oedema (DMO - and will be sold in the EU by Biogen. Like Lucentis, the biosimilar can also be used to treat proliferative diabetic retinopathy (PDR), macular oedema caused by ...